inclusion criteria: * age ≥ 18 years * ≥6 months after kidney transplantation * maintenance immunosuppressive therapy consisting of either triple or dual therapy including mmf/mpa with a minimum daily dose of 1000 mg (mmf) or 720 mg (mpa) and a cni * eligible for the vaccinations as described by the instructions of the manufacturers of the vaccines (e.g. received 3 previous covid-19 vaccinations as part of the primary covid-19 immunisation) * capable of understanding the purpose and risks of the study, fully informed and given written informed consent (signed informed consent form has been obtained) * willing to adhere to the protocol and be available during the study period

inclusion criteria: * age ≥ 18 years * ≥6 months after kidney transplantation * maintenance immunosuppressive therapy consisting of either triple or dual therapy including mmf/mpa with a minimum daily dose of 1000 mg (mmf) or 720 mg (mpa) and a cni * eligible for the vaccinations as described by the instructions of the manufacturers of the vaccines (e.g. received 3 previous covid-19 vaccinations as part of the primary covid-19 immunisation) * capable of understanding the purpose and risks of the study, fully informed and given written informed consent (signed informed consent form has been obtained) * willing to adhere to the protocol and be available during the study period

inclusion criteria: age ≥ 18 years ≥6 months after kidney transplantation maintenance immunosuppressive therapy consisting of either triple or dual therapy including mmf/mpa with a minimum daily dose of 1000 mg (mmf) or 720 mg (mpa) and a cni eligible for the vaccinations as described by the instructions of the manufacturers of the vaccines (e.g. received 3 previous covid-19 vaccinations as part of the primary covid-19 immunisation) capable of understanding the purpose and risks of the study, fully informed and given written informed consent (signed informed consent form has been obtained) willing to adhere to the protocol and be available during the study period

inclusion criteria: age ≥ 18 years ≥6 months after kidney transplantation maintenance immunosuppressive therapy consisting of either triple or dual therapy including mmf/mpa with a minimum daily dose of 1000 mg (mmf) or 720 mg (mpa) and a cni eligible for the vaccinations as described by the instructions of the manufacturers of the vaccines (e.g. received 3 previous covid-19 vaccinations as part of the primary covid-19 immunisation) capable of understanding the purpose and risks of the study, fully informed and given written informed consent (signed informed consent form has been obtained) willing to adhere to the protocol and be available during the study period